Pages Menu
TwitterRssFacebook
ISSN (Online): 2454-1680

OncoExpert

INTERNATIONAL JOURNAL OF INTEGRATED ONCOLOGY

An Official Publication Of Society Of Pharmaceutical Science & Research
Categories Menu

Most Cited

 
Title
Views
PDF
Cited
7.

CONCOMITANT CHEMORADIATION IN HEAD AND NECK CANCER: ROLE OF 5-FU ANALOGS.

Head and neck cancer forms the major chunk of cancer patients in developing country like India. About 2/3rd of the patients present in locally advanced stage in which the cure rates are low. Concomitant chemoradiation with platinum compounds is the standard treatment for such patients as it offers organ and function preservation with better quality of life. MACH-NC update (2009) shows that concomitant chemoradiation provides an absolute survival benefit of 6.5% at 5 years. Many chemotherapeutic agents including 5-FU, taxanes and biologically targeted therapy have been investigated in an effort to maximize the locoregional and survival in locally advanced head and neck cancer. Oral chemotherapeutic agent gives the ease of self medication on daily basis without the need for hospital admission and intravenous infusion. Theoretically daily administration of oral chemotherapy agent mimics the continous infusion of a parenteral agent. Since infusional 5-FU along with Radical RT has achieved a complete response rate of 68% for 5-FU arm versus 56% for placebo arm (p=0.04) with the overall median survival of 33 months for 5-FU versus 25 months for placebo arm, Capecitabine (analog of 5-FU) in low doses have been used in concomitant setting for locally advanced head and neck cancer. Overall response rate observed has been 33-89% with manageable toxicity and near total patient compliance. The maximally tolerated dose to be given daily during radiation therapy is 500 mg/m2 b.i.d. Lower dose doses of 250-350 mg/m2 have also been used in concomitant with lesser toxicity and greater...

Kailash Mittal, Anil Kumar Dhull, Rajeev Atri, Rakesh Dhankhar, Vivek Kaushal

Dr. Kailash Mittal, Assistant Professor, Department of Radiotherapy, UPRIMS&R, Saifai, Etawah (U.P.) INDIA

DOI:

35-46

2607

16

0

1.

PALLIATIVE CHEMORADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR MANAGEMENT OF LOCALLY ADVANCED HEAD & NECK CARCINOMA PATIENTS WITH POOR PERFORMANCE STATUS

Introduction: Palliative external beam radiotherapy (EBRT) and chemotherapy is commonly practiced for management of locally advanced head & neck carcinoma (LAHNC) patients with poor performance status. This study compares EBRT alone and EBRT along with low dose Gemcitabine. Method: Study was conducted in Department of Radiotherapy, PGIMS Rohtak, in 2008-09; on histopathologically proven, untreated 60 cases of LAHNC, having KPS 60-70. Patients were randomly assigned either control group (n=30), given EBRT alone as 20Gy/5Fr/5days or study group (n=30), given EBRT as 20Gy/ 5Fr/ 5days and Gemcitabine 200 mg/m2 i.v. 2 hour prior to radiotherapy on day 1. Mean age was 53 years (26-84 years). Male:female ratio was 5:1. Most common primary site was base of tongue followed by larynx. Major symptoms were pain, difficulty in swallowing and altered voice. Patients were staged as per AJCC 2002; 2/3rd were stage IVA and 1/3rd were IVB. Despite randomization, there was no significant difference between two groups in age, sex, primary site, stage, and performance status. The side effects were graded as per RTOG criteria. Results: Objective response, 3 months post-treatment, in the chemoradiotherapy and radiotherapy alone group respectively was: CR 7% vs 0%; PR 30% vs 33%; stable disease 56% vs 46% and progressive disease 7% vs 20%. Subjective response, similarly was better in study group through out; even significantly better in dysphagia at 3 months follow up. Acute skin reactions were: Grade I- 73% vs 47% at 2 weeks and 60% vs 40% at 1 month respectively. Acute mucosal reactions were: Grade I- 30% vs 17%, Grade II- 43% vs 17% respectively. No hematological and grade III/IV skin or mucosal reactions observed. Differences in reactions were not statistically significant. Conclusion: In management of LAHNC patients with poor performance status, addition of low dose Gemcitabine to palliative radiotherapy gives better disease control and symptomatic relief without unmanageable side...

Dinesh Ranga, Yashpal Verma, Ashok K. Chauhan, Ramesh Sabharwal, Mukesh Bharti

Dr Yashpal Verma, Medical Officer, Department of Radiotherapy, Post-graduate institute of medical sciences, Rohtak (INDIA).

DOI:

01-09

2054

863

0

2.

Radiation induced Dysphagia in head and neck cancers-assessment and management

Disease and treatment-related swallowing dysfunction are quite common in head and neck malignancies. Though the use of high-end technology like Intensity modulated radiotherapy (IMRT) has led to a reduction in morbidity still, the issue of tolerability comes whenever a higher dose of radiation is used for tumor control. The goal of this review is to emphasize the need for documentation of pretreatment swallowing functions and look into the prospects to improve swallowing function, thence quality of life after radiotherapy by studying factors leading to this impairment. We also looked into the benefit of physiotherapy exercises to increase the capacity of...

Shailley A Sehgal, Yashpal Verma, Ashok K Chauhan

Dr Shailley Senior Resident, Department of Radiation Oncology, Pt. B. D. Sharma PGIMS, Rohtak(India)-124001

DOI:

07-14

1204

304

0

8.

TARGETING IMMUNITY TO TREAT CANCERS- A BRIEF REVIEW

Cancer cells have a multitude of mechanisms to avoid and suppress immunity. Normal cells when exposed to chemical carcinogens, irradiation and certain viruses get transformed to cancer cells which can grow indefinitely. These cells have decreased requirements for growth factors; do not undergo apoptosis resulting in malignancy. The tumor cells have various antigens which are responsible for the generation of immune responses towards that particular tumor. There are two types of tumor antigens; tumors specific transplantation antigens (TSTAs) and tumor associated transplantation antigens (TATAs). The TSTAs are specific to tumor, result from mutations which alter the cellular proteins while TATAs may be proteins present in or during some stages of fetal development but not expressed or expressed at low levels in normal adult cells. Adoptive T-cell therapy involves the ex vivo cultivation of T cells with activity against a specific target cancer antigen to increase the frequency of these T cells to achieve therapeutic levels and then infuse them back into the patient. Oncolytic viruses selectively infect, replicate in, and kill tumor cells with no or limited impact on normal tissues which means that tumor cells have surface receptors to bind the virus. Monoclonal antibodies (mAbs) are immunoglobulins derived from a single clone of B cells, act by targeting an antigen which acts a ligand of receptor involved in signal transduction within the...

Nidhi Tejan, Varsha Gupta

Dr. Nidhi Tejan, Senior Resident, Department of Microbiology, SGPGI, Luknow, INDIA

DOI:

47-55

2414

1242

0

1.

PRIMARY LEIOMYOSARCOMA OF TESTIS: A RARE TESTICULAR TUMOUR WITH BETTER OUTCOME

ABSTRACT Aim of the Study: To review and suggest treatment approach for rare diseases Leiomyosarcoma of testis. Material and Method: Here, we have reviewed management of Primary Leiomyosarcoma of the testis by search of case reports in PubMed Central, Embase, Cochrane, and Web of Science Central database. We have classified the obtained information as per Oxford Centre for Evidence Based Medicine (OCEBM) level of evidence, and National Comprehensive Cancer Network (NCCN) Categories of Evidence and Consensus. Here, current treatment scenario for sarcoma and its outcome will be discussed for a new case of low grade primary leiomyosarcoma of testis that was confirmed with Immuno-histochemistry after high inguinal orchidectomy, for painless testicular mass. Systematic review, line listing of old reported cases and treatment evidences were analysed by reviewing various international databases. Results: Leiomyosarcoma is a very rare disease, and only few cases have been reported on online databases. It is usually reported among elderly men following irradiation or long-term anabolic steroid use. Intensive search reveals lack of definitive guidelines for management of leiomyosarcoma because available evidence is level V as per OCEBM and level C as per NCCN. Conclusion: Even though early diagnosis and treatment by high inguinal orchidectomy improves survival and decreases risk of recurrence of leiomyosarcoma, there is need of research and definitive chemotherapy guidelines, similar to sarcoma of other site of the...

Divyesh S. Rana, Vimal D. Batra, Chirag B. Mistry, Anil K. Goela

Dr. Divyesh Rana, Department of Radiotherapy, Medical College and SSG Hospital Baroda, Sayajigunj, Vadodara, Gujrat, India

DOI:

01-09

3320

959

0

1.

ASSESSMENT OF AWARENESS AND KNOWLEDGE ABOUT ORAL CANCER AMONG DENTAL PATIENTS IN BENGALURU.

Objective – Oral cancer is increasing at an alarming rate worldwide and is associated with heightened morbidity and mortality rates. Awareness regarding the signs and symptoms followed by early detection is the key for reducing the same. The present study was taken up to assess the awareness and knowledge regarding oral cancer among dental patients in Bengaluru (INDIA). Method – Study included 400 dental patients who visited the outpatient department of the institution. A questionnaire, adopted and modified from HOCKS scale (mHOCKS), was used to assess the awareness regarding risk factors, knowledge regarding symptoms and signs of oral cancer and general beliefs. Results –The total percentage scores obtained for awareness regarding risk factors, knowledge regarding symptoms and signs of oral cancer and general beliefs of oral cancer were 74.9%, 58.6% and 92.2% respectively. Irrespective of the age and gender, most of the subjects believed that it is easy to treat oral cancer, if detected early. Overall, the score of awareness and knowledge regarding oral cancer in the high-risk population of Bengaluru was, fairly good (75.23%).Conclusion – Although, the study group was having a sound knowledge regarding risk factors, unfortunately knowledge regarding the signs and symptoms of oral cancer was considerably lower. This is especially important for the clinicians, various governmental and non-governmental organization’s in providing specific goals, to concentrate on improving public knowledge about features of oral...

Anju Redhu, Suman B, Monica Venugopal, SindhuIyengar

Dr. Anju Redhu Senior Resident, Department of Oral Medicine and Radiology, Pt. B. D. Sharma PGIMS, Rohtak (INDIA) -124001

DOI:

1-8

954

266

0

9.

UNVEILING THE MYSTERIOUS WORLD OF SALIVARY DUCT CARCINOMA OF THE PAROTID GLAND- A RARE CASE REPORT AND REVIEW OF THE LITERATURE.

Among many variants of salivary gland tumors, salivary duct carcinoma (SDC) of the parotid gland is a highly aggressive and rare malignant tumor which ranks among those with the worst prognosis and a significant mortality. These tumors got their name based on its microscopic resemblance and being analogous to similar schemes in the ductal carcinoma of the breast. The characteristic microscopic features of salivary duct carcinoma are composed of comedo necrosis, a cribriform and papillary pattern of intraductal growth and aggressive infiltration to adjacent structures. Majority of cases are typically treated with radical parotidectomy with or without neck dissection followed by adjuvant radiotherapy. We present a case of a 60 year old male patient who presented with progressive facial paralysis and right parotid swelling. FNAC was positive for malignancy. PET-CT showed a lesion in right superficial lobe of parotid with bilateral neck nodes. Patient underwent right total parotidectomy with right radical neck dissection and left modified neck dissection. Facial nerve was preserved. Microscopic examination reported it as a salivary duct carcinoma, positive for Her2/neu antibody with lymph node metastasis (22/23). Patient received adjuvant radiotherapy and 12 cycles of Transtuzumab. There were no recurrences or metastases within 12 months of...

Irfan Bashir, Sunny Jain, Anil Thakwani, Anshul Bhatnagar, Kundan S. Chufal.

Dr. Irfan Bashir. Batra Cancer Centre, Batra Hospital and Medical Research Centre, 1 Tughlaqabad Institutional Area, M. B. Road, New Delhi, India.

DOI:

56-61

1741

1232

0

1.

GESTATIONAL TROPHOBLASTIC DISEASE AND NEOPLASIA: DILEMMA AND UPDATES!

Gestational trophoblastic diseases include hydatidiform moles and gestational trophoblastic neoplasia i.e. invasive mole, choriocarcinoma, placental site trophoblastic tumor and epitheloid trophoblastic tumor. Incidence from India has been reported up to 2.4/ 1000 pregnancies, 2.5/ 1000 deliveries and 2.6/ 1000 live births. The standard protocols for management exist and are evolving fast. Though all gestational trophoblastic diseases are not malignant, still these need to be managed intensively, because of their potentially life threatening complications and common occurrence in fertility age group females. The better aspect is that; if timely and standard interventions are made; these are highly curable conditions, even with preservation of reproductive...

Dr. Yashpal Verma

Medical Officer, Civil Hospital, Sonepat (INDIA)

DOI:

1-9

2328

585

0

2.

BIOMARKERS IN BREAST CANCER

Biomarkers are the molecules or tissue based processes that indicate future behavior of the cancer. Broadly classified as tissue-based and blood-based biomarkers, these need special assays over and above the routine clinical, radiological and histopathological examination. Potential of tumor biomarker ranges from risk determination through screening, differential diagnosis, prognosis and prediction to monitoring the disease. Breast cancer is the leading cause of cancer related deaths among women. With progressively better understanding of tumor biology, clinical implications of the molecular behavior are being explored for better therapeutic gains in such patients. Though, to date we have limited range of clinically useful biomarkers in breast cancer; their potential may guide us for cancer therapy in future....

Preeti Chauhan, Lalit kumar, Palki Sahib Kaur, Arockia M Babu, Ramesh Sabharwal, Yashpal Verma

Preeti Chauhan, Assistant professor, Department of Biotechnology, Chandigarh College of Technology, Mohali (INDIA)

DOI:

9-15

985

203

0

10.

DESMOID TUMOR OF ANTERIOR ABDOMINAL WALL: A CASE REPORT AND REVIEW OF RECENT MANAGEMENT STRATEGIES

Desmoid tumor is a slow growing neoplasm with aggressive infiltration of adjacent tissue with very rare metastatic potential. We report a 35 years old female patient with desmoid tumor of the anterior abdominal wall who underwent primary resection followed by mesh pasty. Patient had a past history of abdominal surgery in form of caesarean section, and after 5 years of surgery, she presented with a lump over right hypochondrium since last one year. Patient was assessed before surgery by clinical evaluation, abdominal ultrasound, computerized axial tomography scanning (CT scan), magnetic resonance imaging (MRI), and histopathology and immunohistochemistry report.Patient was operated with wide local excision of rectus abdominis muscle mass with meshplasty under general anaesthesia. After all, histology in this case revealed a desmoid tumor with negative β-Catenin report of operated tissue. In view of the negative surgical margins, patient has been put on regular follow...

Divyesh Rana, Anil Goel, Vimal Batra

Dr . Divyesh Rana, Department of Radiotherapy, Medical College and SSG Hospital Baroda, Vadodara, Gujarat, India 39000.

DOI:

62-67

3334

3608

0

Page 1 of 41234